Form 4: STERIS plc Executive Granted Shares and Stock Options, Boosting Insider Holdings

John Adam Zangerle, Senior Vice President, General Counsel, and Secretary of STERIS plc, has acquired 3,756 ordinary shares and 13,360 employee stock options as part of a compensation grant.

Summary

• John Adam Zangerle, Sr. VP, Gen Counsel, and Sec. of STERIS plc, acquired 3,756 ordinary shares on June 3, 2025, at a price of $0.00 per share, likely as a grant or vesting event.
• Following this transaction, Mr. Zangerle beneficially owns a total of 36,163 ordinary shares, of which 10,089 are restricted and subject to various vesting schedules through June 5, 2028.
• Additionally, Mr. Zangerle acquired 13,360 employee stock options on June 3, 2025, with an exercise price of $267.66 per share.
• These options become exercisable in four equal tranches of 3,340 shares annually, starting June 3, 2026, and concluding June 4, 2029, with an expiration date of June 3, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grants of shares and options to a key executive align their interests with shareholders, which is generally viewed favorably. It's a routine compensation event, not indicative of extraordinary news.

Positives

• The acquisition of additional shares and stock options by a senior executive aligns management's interests with those of shareholders, potentially indicating confidence in the company's long-term performance.
• The grants are part of a structured compensation plan, which is a common practice for retaining and incentivizing key personnel.

Future Outlook

The document details future vesting schedules for restricted shares and exercisability dates for stock options, indicating a long-term incentive structure for the executive.

Industry Context

This Form 4 filing reflects a routine insider transaction related to executive compensation, a common practice across all industries to align management incentives with shareholder value. It does not provide insights into broader industry trends for medical device or healthcare services companies.

Stakeholder Impact

• Shareholders: The grants align the interests of a key executive with shareholders, potentially fostering long-term value creation.
• Employees: Reflects the company's compensation strategy for senior management, which can influence overall employee incentive structures.

Next Steps

• Continued vesting of 10,089 restricted ordinary shares through June 5, 2028.
• Employee stock options becoming exercisable in tranches from June 3, 2026, through June 4, 2029.

Key Dates

Recommendation

Keywords

STERIS plc, STE, Form 4, Insider Transaction, Executive Compensation, Stock Options, Restricted Stock, Beneficial Ownership, Corporate Governance